Basiliximab is superior to low dose rabbit anti-thymocyte globulin in pediatric kidney transplant recipients: The younger, the better
Authors:
Open Access
- 20 November 2024
- journal article
- letter
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 138 (2) , 225-227
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Efficacy and safety of single‐dose anti‐thymocyte globulin versus basiliximab induction therapy in pediatric kidney transplant recipients: A retrospective comparative cohort studyPediatric Transplantation, 2024
- Low dose rabbit antithymocyte globulin is non-inferior to higher dose in low-risk pediatric kidney transplant recipientsPediatric Nephrology, 2022
- Low-Dose Antithymocyte Globulin Has No Disadvantages to Standard Higher Dose in Pediatric Kidney Transplant Recipients: Report From the Pediatric Nephrology Research ConsortiumKidney International Reports, 2021
- Primary pediatric deceased‐donor kidney transplant recipients outcomes by immunosuppression induction received in the United StatesPediatric Transplantation, 2020
- Comparing Outcomes between Antibody Induction Therapies in Kidney TransplantationJournal of the American Society of Nephrology, 2017